Facebook Pixel Vax Cocktail Endgame Against Covid-19 | BioSpectrum Asia - Business - Bu hikayeyi Magzter.com'da okuyun

Denemek ALTIN - Özgür

Vax Cocktail Endgame Against Covid-19

BioSpectrum Asia

|

BioSpectrum Asia Sep 2021

The world has been under the deadly spell of the coronavirus, with multiple waves of the pandemic decimating lives and economy in a fell swoop. In a record short span of time, numerous vaccines were developed to combat COVID-19. However, the ground reality seems, as per some experts, that administering a mix of vaccines presents better outcomes. Whether this approach holds good, needs a closer look.

- Ayesha Siddiqui

Vax Cocktail Endgame Against Covid-19

Vaccine mixing, which began unintentionally, is now gaining traction. There is a significant interest in mixing two different types of COVID-19 vaccines to mitigate against supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out.

Canada which sort of started this trend unintentionally to manage its vaccine supply issues by allowing the mixing of vaccines. On June 1, 2021, the Canadian health agency, Health Canada asked those who had taken the Pfizer shot to take Moderna’s mRNA vaccine for their second dose. This has helped Canada overcome a supply bottleneck that delayed Pfizer doses in June.

Taking it even further, on June 17, 2021, the Canadian government recommended those who received the AstraZeneca (adenoviral vector-based vaccine) as the first dose should preferably take either the Pfizer or Moderna mRNA vaccine for their second dose. This decision was taken in light of the rare clotting events reported with the AstraZeneca vaccine.

Germany also followed suit by recommending the same AstraZeneca/Pfizer combo. The country reportedly allowed this heterologous approach on efficacy grounds.

In July 2021, Thailand became one of the first in Southeast Asia to officially start mixing vaccines. The country’s National Communicable Disease Committee issued a recommendation to give AstraZeneca jabs as the second dose to individuals who had initially received China’s Sinovac (based on inactivated virus technology), to build stronger immunity against the highly contagious delta variant which has created havoc in the country.

South Korea also introduced mix-and-match inoculations, using the AstraZeneca vaccine for the first dose and Pfizer for the second.

BioSpectrum Asia'den DAHA FAZLA HİKAYE

BioSpectrum Asia

BioSpectrum Asia

India–EU FTA Paves Way for Expanded Healthcare Trade

On January 27, 2026, after years of negotiations, India and the European Union announced a landmark Free Trade Agreement.

time to read

4 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

PreferCo and Glatt to open CoE for precision fermentation bioprocess scale-up in India

In a major boost to Government of India's BioE3 push, German major Glatt and India-based startup PreferCo have announced the launch of \"PreferCo-Glatt Centre of Excellence (CoE) for Bioprocess Scale-Up\" in Hyderabad's Genome Valley.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Women's Health Surge in APAC

The rising burden of diseases such as ovarian cancer, breast cancer, cervical cancer, infertility, etc. is emerging as the key driver of the women's healthcare market across the globe. While North America led the women healthcare market in 2025, Asia Pacific (APAC) is expected to witness the fastest growth this year onwards. As a result, governments across the APAC region, are recognising the importance of women's health and are launching initiatives, particularly under female leaders, to improve access to healthcare services. Moreover, a number of women-led startups are now developing new solutions to address this growing burden of women-associated diseases in the APAC region. Let's take a closer look.

time to read

6 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Hanchor Bio receives US FDA Orphan Drug Designation for HCB101 in gastric cancer

Taiwan-based biotech startup HanchorBio, Inc. has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HCB101 for the treatment of gastric cancer.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Daiichi Sankyo names Dr John Tsai as Global Head of R&D

Japan-based Daiichi Sankyo Company has appointed Dr John Tsai to succeed Dr Ken Takeshita, who is stepping down as Global Head of R&D, effective April 1, 2026.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

"The global trend is moving beyond centralised hubs toward distributed networks and domestic capability"

King Faisal Specialist Hospital & Research Centre (KFSHRC) and US-based Germfree Laboratories have announced a strategic partnership to develop Saudi Arabia's first fully integrated, modular Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus.

time to read

4 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

SEOUL'S RISKY DRUG PRICING RESET

Drug pricing has once again moved to the centre of policy debate in South Korea, with the government recently stepping back from its proposed generic drug pricing reform.

time to read

2 mins

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

Takeda and Iambic sign $1.7 B deal to advance AI driven design of small molecules

Iambic, a US-based clinical-stage life science and technology company developing novel medicines using its artificial intelligence (AI)-driven discovery and development platform, has announced a multi-year technology and discovery collaboration agreement with Japan-based Takeda Pharma that will use Iambic's industry leading AI drug discovery models to advance a select set of high-priority small molecule programmes, initially in Takeda's Oncology and Gastrointestinal and Inflammation therapeutic areas.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

BioSpectrum Asia

S.Biomedics announces partnership with Catalent to develop and manufacture TED-A9

US-based Catalent and South Korea-based S.Biomedics have announced a strategic partnership to support the development and manufacturing of TED-A9, S.Biomedics' allogeneic pluripotent stem-cell-derived ventral midbrain-specific dopaminergic precursor cell therapy being developed for the treatment of Parkinson's disease.

time to read

1 min

BioSpectrum Asia March 2026

BioSpectrum Asia

China revises drug administration regulations to spur innovation

China has revised regulations concerning drug administration in a bid to promote drug innovation, strengthen management of online sales of medicines and reinforce drug safety supervision.

time to read

1 min

BioSpectrum Asia March 2026

Translate

Share

-
+

Change font size